Surrozen, Inc. SRZN
32.32 USD +0.71 (+2.25%)
Regular-session close
32.32 0.00 0.00%
After hours · Nov 16, 4:00 PM ET
30.78 Day range 33.09
12.52 52-week range 37.83
- YTD
- +43.01%
- 1 year
- +149.00%
News
defenseworld.net Head to Head Contrast: Surrozen (NASDAQ:SRZN) vs. Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Surrozen (NASDAQ: SRZN - Get Free Report) and Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two…
globenewswire.com Surrozen Announces Pricing of $60 Million Underwritten Offering of Common Stock SOUTH SAN FRANCISCO, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the…benzinga.com Guggenheim Maintains Buy on Surrozen, Raises Price Target to $80 Guggenheim analyst Yatin Suneja maintains Surrozen (NASDAQ:SRZN) with a Buy and raises the price target from $42 to $80.
benzinga.com Cantor Fitzgerald Maintains Overweight on Surrozen, Raises Price Target to $62 Cantor Fitzgerald analyst Steve Seedhouse maintains Surrozen (NASDAQ:SRZN) with a Overweight and raises the price target from $40 to $62.
globenewswire.com Surrozen Reports Third Quarter 2026 Financial Results and Provides Business Update First patient dosed in Phase 1b of DUET study evaluating SZN-8141 in patients with diabetic macular edema DUET Phase 2a enrollment to be expanded from approximately 60 to 150 patients to enable a…
